Navigation Links
Contract Research Organization, WCCT Global Announces Strong Focus for Early Phase Research for Obesity
Date:3/25/2013

Costa Mesa, Ca (PRWEB) March 25, 2013

Contract Research Organization, WCCT Global, today announced they are implementing a strong focus on clinical research for obesity treatments. The World Health Organization has alerted the public and medical community that obesity has been on the rise for the last 20 years and continues to grow. With this epidemic continually mounting, WCCT Global is focusing resources on early phase research to treat individuals suffering from obesity. They have done this by establishing a database of over 7,000 people who are stratified by BMI and can be categorized as either overweight or obese. These individuals have expressed the desire to participate in clinical research in obesity. There are four areas of research that would coincide with the characteristics of the WCCT Database: weight loss (appetite suppressant), type 2 diabetes, hypertension and cholesterol / triglyceride control. The demand for safe and reliable treatments for these obesity-associated morbidities is growing at a rapid rate. WCCT Global has conducted multiple clinical studies in all three of these areas. Dr. Mel Affrime, Sr.VP, Translational Medicine for WCCT Global states, “Obesity is a leading cause of death in millions of people each year. The obesity epidemic only continues to grow as many of us continue to live unhealthy lifestyles with our unhealthy diet and lack of regular exercise. Therefore, WCCT Global looks forward to participating in the public health efforts in obesity to hopefully begin to control of this problem within the next decade.”

WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.

If you would like to request information about how WCCT Global can assist your organization with a clinical study, please CLICK HERE.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10557725.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Arizona State University secures defense contract
2. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
3. Local Woodinville Contractor, Washington State Kitchen and Bath, Combats Toxic Mold, Adhering to the Toughest Mold Protection Standards in the Nation with New Promotion
4. Collagenase for Dupuytrens contracture: Added benefit not proven
5. BMC awarded contract to study validity of primary care drug screening tools
6. Federal government renews contract for collecting and maintaining national stem cell transplantation database
7. NIH awards Georgia malaria research consortium up to $19.4 million contract
8. Care2Learn/Upstairs Solutions and Jarlette Health Services Sign Multi-Year Contract for Online Training and Record-Keeping
9. NHS consultant contract fails to increase productivity
10. PLEXERA® LLC Launches Contract Research Services Business for Biomolecular Interaction Studies
11. Securityhunter, Inc. Selected as a Top 25 Baltimore Defense Contractor for the Baltimore Business Journal's 2013 Book of Lists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology: